Unlocking Potential: Using Non-Viral DNA Vectors for TCR Engineering
Time: 11:30 am
day: DAY TWO TRACK 1 B
Details:
- Explore how non-viral vectors mitigate risks associated with insertional mutagenesis, ensuring safer TCR-T therapies
- Discuss the streamlined clinical-scale manufacturing processes of non-viral methods, reducing costs, accelerating production timelines, and reducing complexities in TCR-T cell therapy development
- Delve into the controlled gene expression and broader applications for DNA Vectors, enabling more efficient, economical, and safer genetic engineering of cells
